{"id":"dose-d3-of-interleukin-2","safety":{"commonSideEffects":[{"rate":"null","effect":"Flu-like symptoms"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Interleukin-2 is a cytokine that plays a crucial role in the immune response, particularly in the activation and proliferation of T-cells. It is used to treat various types of cancer, including melanoma and renal cell carcinoma.","oneSentence":"Interleukin-2 stimulates T-cell proliferation and activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:34:33.976Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT01862120","phase":"PHASE2","title":"Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-06-27","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT02659657","phase":"PHASE2","title":"Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2015-03","conditions":"Acute Graft-versus-host Disease","enrollment":70},{"nctId":"NCT03778619","phase":"PHASE1, PHASE2","title":"MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin","status":"UNKNOWN","sponsor":"GC Cell Corporation","startDate":"2018-11-28","conditions":"Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Dose D3 of interleukin-2","genericName":"Dose D3 of interleukin-2","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interleukin-2 stimulates T-cell proliferation and activation. Used for Melanoma, Renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}